Seattle Genetics appoints Roger D. Dansey, M.D., CMO
Seattle Genetics announced the appointment of Roger D. Dansey, M.D., as CMO. Dr. Dansey was most recently at Merck Inc. where he was Therapeutic Area Head for Late Stage Oncology, responsible for the ongoing registration efforts for KEYTRUDAź (pembrolizumab) across multiple tumor types. May 17, 2018